These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 31855875)

  • 21. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
    Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
    Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
    Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
    Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of postoperative lymph node status on the prognosis of esophageal squamous cell carcinoma after esophagectomy following neoadjuvant chemoradiotherapy: a retrospective study.
    Sun Z; Xu X; Zhao X; Ma X; Ye Q
    J Gastrointest Oncol; 2021 Dec; 12(6):2685-2695. PubMed ID: 35070398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 27. Postoperative Adjuvant Therapy Improves Survival in Pathologic Nonresponders After Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma: A Propensity-Matched Analysis.
    Hsu HY; Chao YK; Hsieh CH; Wen YW; Chang HK; Tseng CK; Liu YH
    Ann Thorac Surg; 2016 Nov; 102(5):1687-1693. PubMed ID: 27457831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
    Chen WH; Huang YL; Chao YK; Yeh CJ; Chang HK; Tseng CK; Liu YH
    Ann Surg Oncol; 2015 Jan; 22(1):338-43. PubMed ID: 25023545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial.
    Zhan M; Zheng H; Yang Y; Xu T; Li Q
    Radiother Oncol; 2019 Dec; 141():27-32. PubMed ID: 31431378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The patterns and risk factors for relapse in oesophageal squamous cell cancers that achieve pathological complete response to neoadjuvant chemoradiotherapy.
    Zhong J; Fang S; Chen R; Yuan J; Xie X; Lin T; Liu M; Liu Q; Fu J
    Eur J Cardiothorac Surg; 2024 Jun; 65(6):. PubMed ID: 38810125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
    Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early Recurrence and Cancer Death After Trimodal Therapy for Esophageal Squamous Cell Carcinoma.
    Hamai Y; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Furukawa T; Kurokawa T; Ohsawa M; Okada M
    Anticancer Res; 2019 Mar; 39(3):1433-1440. PubMed ID: 30842179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma.
    Lu H; Liu JF; Rong Y; Liu XB; Wang Y
    J Gastrointest Surg; 2024 Jun; 28(6):867-869. PubMed ID: 38570232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased resected lymph node stations improved survival of esophageal squamous cell carcinoma.
    Lu RD; Wei ZD; Liu YX; Tian D; Zhang HL; Shang QX; Hu WP; Yang L; Yang YS; Chen LQ
    BMC Cancer; 2024 Feb; 24(1):177. PubMed ID: 38317075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Extracapsular Lymph Node Involvement After Neoadjuvant Chemoradiation Therapy Followed by Surgery in Carcinoma of the Esophagus: A Multicenter Study.
    Depypere LP; Moons J; Mariette C; D'Journo XB; Thomas PA; Hölscher AH; Bollschweiler E; van Berge-Henegouwen MI; Van Lanschot JJB; Lerut TEMR; Nafteux PR
    Ann Surg; 2018 Dec; 268(6):1000-1007. PubMed ID: 28742714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.